Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL114 Administered in Subjects With Non-Hodgkin's Lymphoma

NCT05144347 is registered in ClinicalTrials.gov with Exelixis as lead sponsor.

NCT NCT05144347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05144347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL114 Administered in Subjects With Non-Hodgkin's Lymphoma
Lead sponsor
Exelixis
Phase
Phase 1
Overall status
Terminated
Start date
April 12, 2022
Completion date
November 1, 2022
Enrollment
2 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

activated b-cell type diffuse large b-cell lymphoma (abc-dlbcl), chronic lymphocytic leukemia (cll), mantle cell lymphoma (mcl), non-hodgkin's lymphoma (nhl), small lymphocytic lymphoma (sll)